🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

17 results for “Compass” Clear

  1. COMP360 psilocybin

    Compass Therapeutics

    PTSD - Post Traumatic Stress Disorder

    phase 3 small molecule active

    1 trial

  2. CTX-009

    Compass Therapeutics

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  3. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen Technology (Ireland) UC

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  4. Psilocybin

    Compass Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    2 trials

  5. Psilocybin

    Compass Therapeutics

    Treatment Resistant Depression

    phase 3 small molecule active

    7 trials

  6. CTX-009

    Compass Therapeutics

    Glioblastoma

    phase 2 small molecule active

    1 trial

  7. CTX-009

    Compass Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  8. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  9. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  10. Psilocybin

    Compass Therapeutics

    Treatment-Resistant Major Depressive Disorder

    phase 2 small molecule terminated

    1 trial

  11. Psilocybin

    Compass Therapeutics

    Anorexia Nervosa

    phase 2 small molecule completed

    2 trials

  12. Psilocybin

    Compass Therapeutics

    Body Dysmorphic Disorders

    phase 2 small molecule completed

    1 trial

  13. Psilocybin

    Compass Therapeutics

    Post Traumatic Stress Disorder

    phase 2 small molecule completed

    1 trial

  14. CTX-10726

    Compass Therapeutics

    Gastroesophageal Cancer (GC)

    phase 1 small molecule active

    1 trial

  15. CTX-471

    Compass Therapeutics

    Locally Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  16. CTX-8371

    Compass Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  17. Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    approved other terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources